Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Prices $7.5M Public Offering of Stocks, Warrants

NEW YORK (GenomeWeb) – Biocept today priced its public offering of 6.25 million shares of its common stock and warrants to purchase up to 6.25 million shares of the common stock.

Each share of stock is being sold with one warrant to purchase one share of common stock at a combined price of $1.20 per share and warrant. Gross proceeds from the offering are expected to be about $7.5 million.

The warrants, Biocept said, will be exercisable at $1.20 per share and will expire five years from the date of issuance. The offering is expected to close on or about Feb. 12. Maxim Group is the book-running manager and Dawson James Securities is the co-manager on the offering.

Biocept has granted the underwriter a 45-day option to purchase an additional 937,500 shares of common stock and/or warrants to purchase up to 937,500 shares of common stock at $1.20 per share.

The San Diego-based company said in a document filed with the US Securities and Exchange Commission that it intended to offer about 3.6 million shares of its common stock and warrants to purchase another 3.6 million shares of common stock at about $2.11 per share and warrant for net proceeds of about $6.8 million, or $7.8 million if the underwriter exercised its option in full.

Biocept said in its document that proceeds would go toward general corporate purposes and ongoing operations, as well as expansion of the business.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.